Semi-Synthetic Compound Shows Promise Against Drug-Resistant Tuberculosis

A recent study published in Microbiology Spectrum describes a promising new compound for combating tuberculosis (TB), including drug-resistant strains. The research team, led by Jim Sun from the University of British Columbia, developed a semi-synthetic compound derived from sanguinarine, a natural antimicrobial agent found in North American flowering plants.

The new compound, named BPD-9, was created by redesigning sanguinarine to enhance its antibacterial properties while reducing toxicity. In laboratory and animal studies, BPD-9 demonstrated effectiveness against Mycobacterium tuberculosis strains resistant to front-line TB antibiotics. Notably, it also showed efficacy against dormant and intracellular M. tuberculosis, addressing key limitations of current TB treatments.

BPD-9's specificity for pathogenic bacteria within the Mycobacterium genus suggests it may have less impact on beneficial microbiota compared to broader-spectrum antibiotics. This selectivity could potentially lead to fewer side effects in clinical applications.

Dr. Sun highlighted the compound's unique properties in combating M. tuberculosis and its potential for clinical development. “Our finding that the new compound is effective against other members of the Mycobacterium genus may also prove to be valuable in the fight against deadly lung infections caused by non-tuberculous mycobacteria, which are notoriously resistant to most antibiotics. It is also enticing to speculate that BPD-9 could be killing Mycobacterium tuberculosis in a way that is different than that of existing anti-TB drugs.”